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Combination strategies surely play a crucial role in treatment of cancer. Stereotactic ablative radiotherapy (SABR)
has been described to induce abscopal effects particularly in renal cell cancer metastases. This effect is a reaction
induced following irradiation of tumour tissue and occurring in another metastatic location outside the treatment
field. However, this effect is limited and occurs sparsely in about 1-5% of patient. We are planning to improve the
clinical outcome of this treatment in metastatic solid tumours by combining SABR with sequential
immunotherapeutic treatments including vaccination strategies, adoptive cell therapy, cytokine therapy, or
anti-CTLA-4 therapy.Commentary
Combination strategies in treatment of human diseases
in general and of cancer in particular are necessary.
Combination of surgery, radiotherapy, and chemother-
apy has been the standard care for treating several
tumours [1,2]. In Sweden, the area of application of
radiotherapy and in particular stereotactic ablative radio-
therapy (SABR), has increased during the last decade
[3-7]. Previous experience of SABR in the treatment of
renal cell carcinoma (RCC) metastases showed a high
local control (90%) at different tumor locations as docu-
mented by others and us [3–5,8,9]. The occurrence of
distant micro-metastases not visualized on CT and PET
remain a treatment problem. Even if the local control is
high after SABR in various tumor diagnoses most
patients will recur with new metastases due to the oc-
currence of distant micro-metastases not visualized on
CT or PET/CT.
In renal cancer there have been reports on abscopal
effects on distant metastases where non-irradiated tumors
have regressed temporarily or seemingly permanently after* Correspondence: Giuseppe.Masucci@ki.se
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reproduction in any medium, provided the ortreatment with SABR of either the primary tumour or
other metastatic lesions [10]. The “abscopal effect” is the
occurrence of objective tumor regressions induced follow-
ing irradiation in sites outside the irradiated field.
This phenomenon has been reported in various tumor
forms but mainly as singular events [11]. Recent evidence
that radiation induces immunogenic tumor cell death
and alters the tumor microenvironment to enhance re-
cruitment of antitumor T cells supports the hypothesis
that radiation can enhance both the priming and the ef-
fector-phase of the antitumor immune response [12,13].
Leukocytes phenotyping is needed to determine the
underlying mechanisms for these abscopal effects. SABR
treatment of inoperable renal cancer results in local
tumor sterilization with release of tumour cell fragments
containing molecules that may be immunogenic. For in-
stance, apoptosis, a form of cell death originally consid-
ered as non-immunogenic and non-inflammatory, has
recently been demonstrated to be immunogenic when it
is induced by drugs like anthracyclines or by ionizing ra-
diation [14,15]. These tumour antigens are taken up lo-
cally and systemically by antigen presenting cells,
particularly the dendritic cells (DC), which have the po-
tential to stimulate de novo production of specific im-
mune responses (either cellular or humoral) or enhance,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion of tumor immunity to these tumor antigens is, how-
ever, regulated by cells and molecules with the ability to
inhibit immune responses particularly to “self” tumor
antigens. Through administration, for instance, of anti-
CTLA-4 antibodies these immune regulatory mechan-
isms can be halted or diminished in activity, resulting in
an activation of the anti-tumor responses to the antigens
released by SABR, and thus acting in synergy with SABR
[16].The collaborative units at our department are dis-
cussing and planning different strategies on this thera-
peutic combinations. Additional activation of anti-tumor
immunity can also be obtained by administration of au-
tologous DC, produced ex vivo from autologous leuka-
pheresis derived monocytes, with the capacity to take up
the circulating tumor antigens released by SABR for effi-
cient priming of T cells. Alternatively, autologous DCs
can be “pulsed” ex vivo with tumor derived material and
provided as a tumor vaccine with the capacity to re-acti-
vate the patients anti-tumor response. Yet another
principle of anti-tumor treatment which can be applied
to these patients would be to adoptively transfer tumor
specific T cells, derived either from Tumor Infiltrating T
cells ( TIL ) or from autologous T cells retroviral trans-
duced with tumor specific T cell receptors ( TCRs). SABR
creates an inflammatory environment that may augment
the activity of adoptively infused TILs. Consequently, we
consider that the rationale beyond these strategies is:
a. to improve the clinical outcome of metastatic solid
tumours (renal cell cancer, malignant melanoma,
lung cancer etc) by combining the SABR with
indirect induced immune re-activation;
b. to elicit an “abscopal effect” by sequential treatment
with immunotherapeutic principles such as (anti
CTLA-4 MoAB, autologous dendritic cells and /or
TIL cells adoptive cell transfer, cytokines (GM-CSF,
Interleukins etc.).
In a clinical trial recording of toxicity as well as tumour
efficacy of the synergistic activity between SABR and the
immune response enhancers are mandatory primary objec-
tives. Furthermore, we intend to analyze markers that can
explain possible mechanisms by establishing blood borne
biomarkers for toxicity and efficacy, using LC-MS/MS; to
analyse, in an unbiased way, the metabolome and proteome
before and at specific times after SABR and added im-
munotherapy. We will elaborate the data by statistical and
bioinformatics tools used at the Karolinska Biomics Centre
which is part of the Eurocan Platform project . Selected
protein biomarkers will be brought to a Luminex based
system for analyses directed to larger materials. Recruit-
ment of the patient cohort include at a first stage patients
with metastatic renal clear cell carcinoma or malignantmelanoma (Stage IV) after progression on third line ther-
apy, with an expected survival of more than 3 months.
Written informed consent will be obtained from the patient
for publication of this report and any accompanying images.
These patients would have at least one metastatic lesion
available for SABR (15Gy x 3) and one marker lesion for
evaluation of effect without SABR. In a planned phase-I
study patients with metastatic solid tumors will be recruited
for a combination treatment of SABR+anti-CTLA4. SABR
will be delivered to at least one metastatic or primary lesion
with a standard dose of 15 Gy x 3 prescribed to the 67%
isodose. This dose has been documented to achieve a high
local control in various tumor types and it is in accordance
with experimental evidence for induction of the abscopal
effect. Anti-CTLA4 will be injected i.v. with 21 days interval
1–2 days post SABR in escalating dose cohorts in order to
determine the maximum tolerated dose of the antibody.
Close monitoring of immunefunctions will be undertaken
to identify optimal immune activating dose.
The combination of the immune triggering effects of
ionizing radiation with new immune regulatory drugs
may leverage the effects of radiotherapy and transform a
local therapy to a novel systemic treatment.
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